Skip to main content
Premium Trial:

Request an Annual Quote

Biocartis 2015 Revenues Jump 57 Percent on Collaborations

NEW YORK (GenomeWeb) – Biocartis reported today a 57 percent increase in revenues for the full year 2015.

The Belgian molecular diagnostics firm said that total revenues climbed to €13.3 million ($15.1 million) from €8.5 million in 2014. Collaboration revenue more than tripled to €9.7 million from €3.2 million a year ago. Product sales revenue dropped 32 percent to €3.6 million from €5.3 million in 2014.

In a statement accompanying the release of results, Biocartis said it added collaborations with Microbiome, Fast-track diagnostics, A*Star, Merck KGaA, and Amgen in 2015.

Grants and other income totaled €1.6 million to bring Biocartis' total operating income to €15 million, up 44 percent from €10.4 million in the prior year.

The firm added that it increased the installed base of its Idylla molecular diagnostics system by 83 instruments to 165.

Biocartis' reported a net loss of €39.8 million, or €1.07 per share, compared to a loss of €9.7 million, or €.36 per share, in 2014.

Biocartis' R&D spending increased 46 percent to €36.6 million from €25 million in 2014, while SG&A spending increased 50 percent to €15.4 million from €10.3 million, driven by increased marketing and distribution expenses. The firm reported adding 12 people to its sales and marketing organization to support commercialization ramp-up.

The firm ended the year with cash and cash equivalents of €104.1 million.           

Biocartis guided for the Idylla installed base to eclipse 300 by the end of 2016, adding an additional 150 to 175 instruments. The firm also said it would launch four new tests — a research-use-only solid biopsy lung cancer panel, a rapid Ebola triage test, a liquid biopsy for colon cancer, and the Idylla MERS test — and would end the year with cash and cash equivalents between €45 million and €55 million.

Biocartis also said it anticipates CE-marking of the Idylla NRAS and NRAS/BRAF solid biopsy test and US Food and Drug Administration approval for the Idylla instrument, console, and respiratory panel. 

The Scan

Genetic Ancestry of South America's Indigenous Mapuche Traced

Researchers in Current Biology analyzed genome-wide data from more than five dozen Mapuche individuals to better understand their genetic history.

Study Finds Variants Linked to Diverticular Disease, Presents Polygenic Score

A new study in Cell Genomics reports on more than 150 genetic variants associated with risk of diverticular disease.

Mild, Severe Psoriasis Marked by Different Molecular Features, Spatial Transcriptomic Analysis Finds

A spatial transcriptomics paper in Science Immunology finds differences in cell and signaling pathway activity between mild and severe psoriasis.

ChatGPT Does As Well As Humans Answering Genetics Questions, Study Finds

Researchers in the European Journal of Human Genetics had ChatGPT answer genetics-related questions, finding it was about 68 percent accurate, but sometimes gave different answers to the same question.